Quality Investor
MarketsPortfolioEvidenceTestedCompareWatchlistAbout 

Nutex Health Inc.

Rank #105HypergrowthWatchlistCompare with other stocks

NUTX · Nasdaq · Healthcare

Nutex Health Inc. (NUTX) — Rank #105 by gross profitability (GP/assets 0.46) · ROE 18.0% · Piotroski F-Score 7 / 9.

As-of 2026-10-30 · CIK 0001479681 · all metrics point-in-time as of the filing date.

About

Nutex Health Inc. operates as a healthcare services and operations company in the United States.

Show more

It operates through three segments: Hospital, Population Health Management (PHM), and Real Estate. The Hospital segment develops and operates a network of micro hospitals, specialty hospitals, and hospital outpatient departments that offer healthcare services, including emergency room care, inpatient care, and behavioural health. It also provides imaging services, such as CT scan, X-ray, MRI, ultrasound, etc.; laboratory services; and onsite inpatient pharmacies. The PHM segment provides management, administrative, and other support services to its affiliated hospitals and physician groups by establishing and operating provider networks, such as independent physician associations (IPAs); and a cloud-based technology platform for IPAs. The Real Estate segment owns and leases land and hospital buildings. Nutex Health Inc.

was founded in 2011 and is headquartered in Houston, Texas.

Industry
Medical Care Facilities
Sector
Healthcare
State
DE
Filer Category
Accelerated filer
Fiscal Year End
December 31

Company Snapshot

P/S is the primary valuation lens — earnings are reinvested, not available for P/E.

Market Cap

—

P/E (annual)

—

P/S (annual)

—

P/B

—

P/OCF (annual)

—

Shareholder Yield

—

Employees

1,037

Industry

Medical Care Facilities

Exchange

Nasdaq

10/12

Flags passed

NUTX passes 10/12 quality flags

2 cautions to review

  • CAUTION
    Dilution above 2%

    Annual share count increase exceeds 2%. May be acceptable for high-growth companies funding talent via stock compensation

  • CAUTION
    Disclosure regression

    A previously-disclosed line item is no longer reported — worth checking the filing for why

  • PASS
    Gross margin holding
  • PASS
    FCF not negative from investment
  • PASS
    Revenue not declining
  • PASS
    Operating margin holding
  • PASS
    Free cash flow intact
  • PASS
    Passes safety gate
  • PASS
    Balance sheet stable
  • PASS
    No competitive retreat
  • PASS
    SBC not compressing margin
  • PASS
    No valuation convergence

Strengths Operating leverage expanding · Sequential beat (rev + EPS)

A count of the 12 warning flags that could be evaluated. Unweighted: colour follows the worst flag.

Quality Profile

Profitability

1/1 pass
GP / assets
0.46
Return on equity
18.0%
Gross margin trend
PASS

Safety

1/1 pass
Balance-sheet safety
PASS
Debt / equity
0.90
Current ratio
5.00×
Net cash
$165.61M

Cash Flow

3/3 pass
Positive FCF
PASS
Cash-backed earnings
PASS
Accruals healthy
PASS
SBC / revenue
12.3%

Growth

1/2 pass
Revenue growth
82.4%
Piotroski F-Score
7 / 9
Share dilution
23.0%

Revenue growth and the path to profitability (margin trend) are the primary reads at this stage.

Profitability

Does it make money well?

No warning flags · GP/assets 0.46

Gross profitability (GP / assets)

0.46

Primary signal (Novy-Marx).

3rd of 11 SIC 7389 peers

Return on equity

18.0%

Gross margin

50.8%

5th of 11 SIC 7389 peers

Revenue growth (YoY)

82.4%

Gross margin improving

Margin trend vs prior year.

PASS

Operating Leverage

2022202320242025
Revenue vs COGS
Revenue vs OpEx
Op. Income vs Revenue

Growth

Revenue CAGR (3Y)

58.6%

Revenue CAGR (5Y)

26.1%

Earnings CAGR (3Y)

—

FCF CAGR (3Y)

89.7%

Cash Flow Health

Is the cash real?

No warning flags · FCF 247% above net income

Free cash flow

$245.60M

Operating cash flow minus capex.

Positive free cash flow

PASS

FCF vs net income

246.9%

(FCF − net income) ÷ |net income|. Positive: cash above earnings. Negative: below.

FCF not below net income

Fails when free cash flow is below net income (yellow flag).

PASS

Accruals healthy

Cash-backed earnings.

PASS

SBC / revenue

12.3%

Stock-based comp intensity.

Balance Sheet Strength

Can it survive a storm?

Caution: Dilution above 2% · net cash $165.61M, F-Score 7/9

Balance-sheet safety

Composite anti-fragile check.

PASS

Debt / equity

0.90

3rd of 10 SIC 7389 peers (best = lowest)

Current ratio

5.00×

2nd of 11 SIC 7389 peers

Quick ratio

2.25×

Net cash

$165.61M

Cash & equivalents minus total debt.

Piotroski F-Score

7 / 9

Fundamental-strength score (0-9).

Valuation

Is the price reasonable?

No warning flags

Capital allocation quality

Composite score

2.7 / 5

Fair
Share count trend
23.0%0/5 Weak
Buyback timing
N/AN/A
Dividend growth consistency(non-payer or broken streak)
0 yr3/5 Good
Net debt trajectory(deleveraging)
14.8%5/5 Strong

Lifecycle Phase History

20202025
Startup
Hypergrowth
Decline

Price History

NUTX-96.5% · -52.9% CAGRSPY+77.1% · +13.7% CAGR

View full financial statements →

Source filings on SEC EDGAR: 10-K annual reports · 10-Q quarterly reports